Phase II Clinical Trial of NEPA (Netupitant/Palonosetron) for Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patient Receiving the BEAM Conditioning Regimen

被引：0
|
作者：
Bubalo, Joseph [1 ]
Chen, Andy I. [2 ]
Leong, Kelli [3 ]
Gille, Bianca [4 ]
Nagle, Sarah [5 ]
Bensch, Kenneth [4 ]
Macey, Tara [4 ]
Ellison, Kelly [4 ]
Booth, Georgeann [4 ]
Misra, Shikha [4 ]
Maziarz, Richard T. [6 ]
机构：
[1] Oregon Hlth & Sci Univ Hosp, Pharm Serv, CR 9-4, Portland, OR USA
[2] Oregon Hlth & Sci Univ, Knight Canc Inst, Ctr Hematol Malignancies, Portland, OR 97201 USA
[3] Oregon Hlth & Sci Univ Hosp, Pharm, Portland, OR USA
[4] Oregon Hlth & Sci Univ Hosp, Portland, OR USA
[5] Oregon Hlth & Sci Univ Hosp, Portland, PA USA
[6] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2019年 / 25卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
414
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Effectiveness of NEPA, an oral fixed-dose combination of NEtupitant and PAlonosetron in the prevention of chemotherapy-induced nausea-vomiting in patient receiving highly emetogenic chemotherapy regimens.
    Jadhav, Amit Y.
    Gupta, Sudeep
    Biswas, Ghanashyam
    Chandrakanth, M., V
    Dattatreya, Palanki Satya
    Thomas, Boben
    Gupta, Sumant
    Bhagat, Sagar B.
    Patil, Saiprasad
    Barkate, Hanmant B.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).
    Aapro, Matti S.
    Rossi, Giorgia
    Rizzi, Giada
    Palmas, Marco
    Grunberg, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
  • [33] Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).
    Aapro, Matti S.
    Rossi, Giorgia
    Rizzi, Giada
    Palmas, Marco
    Grunberg, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron
    Aapro, Matti
    Karthaus, Meinolf
    Schwartzberg, Lee
    Bondarenko, Igor
    Sarosiek, Tomasz
    Oprean, Cristina
    Cardona-Huerta, Servando
    Hansen, Vincent
    Rossi, Giorgia
    Rizzi, Giada
    Borroni, Maria Elisa
    Rugo, Hope
    SUPPORTIVE CARE IN CANCER, 2017, 25 (04) : 1127 - 1135
  • [35] Patient reported outcomes for a fixed combination of netupitant/palonosetron (NEPA) for prevention of nausea and vomiting in patients receiving high-risk platinum chemotherapy - real life data
    Karthaus, M.
    Weslau, M.
    Rezek, D.
    Rauh, J.
    Ulmer, M.
    Schilling, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 38 - 38
  • [36] NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron
    Matti Aapro
    Meinolf Karthaus
    Lee Schwartzberg
    Igor Bondarenko
    Tomasz Sarosiek
    Cristina Oprean
    Servando Cardona-Huerta
    Vincent Hansen
    Giorgia Rossi
    Giada Rizzi
    Maria Elisa Borroni
    Hope Rugo
    Supportive Care in Cancer, 2017, 25 : 1127 - 1135
  • [37] Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: effects on quality of life
    Karthaus, Meinolf
    Oskay-Oezcelik, Guelten
    Wuelfing, Pia
    Hielscher, Carsten
    Guth, Dagmar
    Zahn, Mark-Oliver
    Flahaut, Elisa
    Schilling, Joerg
    FUTURE ONCOLOGY, 2020, 16 (14) : 939 - 953
  • [38] Phase 3 efficacy results of a single dose of NEPA, a fixed combination of netupitant and palonosetron, versus a 3-day regimen of aprepitant/granisetron (APR/GRAN) for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients
    Zhang, L.
    Lu, S.
    Dechaphunkul, A.
    Chessari, S.
    Lanzarotti, C.
    Jordan, K.
    Aapro, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [39] Analysis of Quality-of-Life (QoL) in Patients Receiving NEPA for Prevention of Chemotherapy-Induced Nausea (CINV) and Vomiting
    Karthaus, Meinolf
    Zahn, M. O.
    Tschechne, B.
    Gerber, B.
    Haas, S.
    Schwindel, U.
    Konias, M.
    Rotmann, A. R.
    Schilling, J.
    BLOOD, 2020, 136
  • [40] Analysis of phase III clinical studies for palonosetron, ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).
    Barbour, S. Y.
    Morrow, G. R.
    Ahmed, R.
    Ballinari, G.
    Thorn, M. D.
    Cox, D.
    Schwartzberg, L. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345